Ziccum extends evaluation agreement with global pharmaceutical company
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Lund, November 23, 2021 -- Following positive results Ziccum AB (publ) (‘Ziccum’) has extended its pilot evaluation study agreement with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The study is analyzing Ziccum’s air-drying capabilities on one of Janssen’s vaccine platform technologies, using Ziccum’s ambient air-drying system LaminarPace TM. The study was originally initiated on 3 October 2019. Following positive findings and a successful collaboration it was extended on 25 January 2021. The present extension is for a further six months’ work.
Ziccum CEO Göran Conradson: “We’re very proud to extend this pilot project and move onto the next step. LaminarPace has performed well at each stage, and the extension reflects the promise of this innovative project. We’re delighted to keep partnering with Janssen.”
Ziccum’s ambient air-drying system LaminarPace TM can dry liquid vaccines at room temperature keeping the active ingredient intact. Dry thermostable vaccines could be stored and transported with no need for cold storage or refrigeration. Ziccum has continued to upgrade and optimize key features of LaminarPace TM throughout the time of the study as part of its scale-up towards ultimately preparing the system for GMP (Good Manufacturing Practice) industrial manufacture.